Copenhagen, 2015-03-19 16:15 CET (GLOBE NEWSWIRE) -- The annual general meeting of Exiqon A/S was held today, 19 March 2015, at the Company’s address, Skelstedet 16, DK-2950 Vedbæk, where the general meeting resolved:
1. To adopt the audited annual report.
2. To appropriate the result of the year as proposed in the audited annual report.
3. To approve the supervisory board’s remuneration for 2015 as proposed by the supervisory
board.
4. To re-elect Thorleif Krarup, Erik Walldén, Michael Nobel and Per Wold-Olsen as members
of the company’s supervisory board.
5. To elect Rodney Turner as a new member of the company’s supervisory board.
6. To appoint KPMG Statsautoriseret Revisionspartnerselskab as the company’s new auditor.
7. To delete the maximum age for members of the supervisory board in the articles of
association.
8. To authorize the supervisory board to issue warrants without pre-emption rights for the
company’s shareholders and to implement the corresponding capital increases with a right
to subscribe to up to a nominal amount of DKK 3,687,408 shares, however not exceeding
10% of the issued nominal share capital from time to time and to re-apply or re-issue any
lapsed or non-exercised warrants.
9. To authorize the chairman of the meeting to make amendments and additions to the
resolutions adopted in connection with registration thereof.
At a supervisory board meeting held immediately after the general meeting, the supervisory board elected Erik Walldén as chairman of the supervisory board and Thorleif Krarup as vice chairman of the supervisory board. The composition of the supervisory board is as follows:
Erik Walldén, chairman
Thorleif Krarup, vice chairman
Michael Nobel
Per Wold-Olsen
Rodney Turner
Additional information
Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)
About Exiqon (for the media)
Exiqon operates in two business areas: Exiqon Life Sciences is a leading provider of flexible solutions for RNA analysis used by academia, biotech and pharmaceutical companies around the world to make ground breaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Diagnostics develops novel molecular diagnostic tests for early detection of cancer and treatment selection for patients based on gene activity analysis, using the tools developed by Exiqon Life Sciences. Exiqon is listed on the NASDAQ in Copenhagen. For more information about us, please visit www.exiqon.com
